FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
What happened
In March 2026, FDA reviewed fitish.com and found it offered compounded semaglutide and tirzepatide drug products. FDA said pictured labels named FITISH, suggesting FITISH made the drugs when it does not, and website claims compared the active ingredients to Ozempic, Mounjaro, and Zepbound, implying FDA approval. FDA said these representations made the products misbranded.
What FDA found
The website labels show FITISH on compounded semaglutide and tirzepatide products, suggesting FITISH is the compounder even though the letter says it is not.
FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)The website says semaglutide is the active ingredient in Ozempic, which FDA says implies the compounded product is FDA-approved or evaluated when it is not.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website says tirzepatide is the active ingredient in Mounjaro and Zepbound, which FDA says implies the compounded product is FDA-approved or evaluated when it is not.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says introducing these misbranded drug products into interstate commerce is prohibited.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells FITISH to respond in writing within 15 business days to the Office of Compounding Quality and Compliance, identify the entities that produce the compounded drugs, provide sample labeling, and correct or remove other misleading website claims. It also must investigate root causes and take corrective and preventive measures.
Who should pay attention
- telehealth and e-commerce companies selling compounded GLP-1 drugs
- compounding pharmacies and contract manufacturers whose products are advertised by other brands
- marketing and regulatory teams for wellness brands making drug-related claims
This is a summary. Read the original letter on fda.gov.